Your browser is no longer supported. Please, upgrade your browser.
Atossa Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.81 Insider Own0.04% Shs Outstand120.82M Perf Week17.60%
Market Cap331.06M Forward P/E- EPS next Y-0.21 Insider Trans0.00% Shs Float71.52M Perf Month33.01%
Income-22.30M PEG- EPS next Q-0.05 Inst Own7.70% Short Float14.66% Perf Quarter-29.56%
Sales- P/S- EPS this Y2.70% Inst Trans143.07% Short Ratio0.90 Perf Half Y77.92%
Book/sh1.59 P/B1.72 EPS next Y-10.50% ROA-117.10% Target Price- Perf Year65.06%
Cash/sh0.33 P/C8.36 EPS next 5Y- ROE-166.10% 52W Range0.81 - 5.08 Perf YTD188.42%
Dividend- P/FCF- EPS past 5Y52.40% ROI- 52W High-46.06% Beta2.24
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low238.27% ATR0.26
Employees4 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)66.56 Volatility14.52% 12.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-149.80% Profit Margin- Rel Volume1.58 Prev Close2.36
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume11.64M Price2.74
Recom2.00 SMA2038.38% SMA5020.60% SMA20021.77% Volume18,448,994 Change16.10%
Jan-26-18Initiated Maxim Group Buy $2
Apr-30-21 09:30AM  
Apr-08-21 09:30AM  
Mar-31-21 09:30AM  
Mar-30-21 09:40AM  
Mar-22-21 08:30AM  
Mar-11-21 09:30AM  
Mar-01-21 09:55AM  
Feb-25-21 09:00AM  
Feb-10-21 09:30AM  
Feb-03-21 09:30AM  
Feb-02-21 09:30AM  
Jan-29-21 09:30AM  
Jan-27-21 09:00AM  
Jan-25-21 09:30AM  
Jan-08-21 06:02AM  
Jan-06-21 09:15AM  
Dec-17-20 09:15AM  
Dec-09-20 11:28PM  
Dec-08-20 09:45PM  
Nov-17-20 08:00AM  
Nov-13-20 09:30AM  
Nov-10-20 09:30AM  
Oct-28-20 07:03AM  
Oct-19-20 09:30AM  
Oct-07-20 09:30AM  
Oct-02-20 09:20AM  
Sep-21-20 06:09PM  
Sep-17-20 09:30AM  
Sep-14-20 08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 09:30AM  
Aug-31-20 06:12PM  
Aug-26-20 09:30AM  
Aug-17-20 09:30AM  
Aug-13-20 09:30AM  
Aug-05-20 11:04AM  
Aug-03-20 09:30AM  
Jul-30-20 09:30AM  
Jul-27-20 09:30AM  
Jul-21-20 10:12PM  
Jul-16-20 09:15AM  
Jul-15-20 09:30AM  
Jul-08-20 09:30AM  
Jun-13-20 08:05AM  
Jun-11-20 09:30AM  
Jun-05-20 03:49PM  
May-29-20 08:00AM  
May-28-20 09:30AM  
May-20-20 09:30AM  
May-13-20 09:30AM  
May-07-20 09:30AM  
Apr-27-20 08:00AM  
Apr-22-20 03:40PM  
Apr-20-20 08:00AM  
Apr-17-20 10:51AM  
Apr-16-20 08:00AM  
Apr-02-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 08:00AM  
Mar-13-20 08:30AM  
Mar-02-20 08:30AM  
Feb-05-20 08:00AM  
Feb-04-20 05:10PM  
Jan-22-20 08:30AM  
Jan-06-20 08:00AM  
Dec-19-19 08:30AM  
Dec-16-19 11:09AM  
Dec-05-19 08:30AM  
Nov-13-19 08:00AM  
Oct-23-19 08:30AM  
Oct-16-19 08:30AM  
Oct-15-19 08:30AM  
Sep-30-19 08:30AM  
Sep-06-19 08:30AM  
Sep-03-19 08:00AM  
Aug-13-19 01:26PM  
Jul-30-19 08:30AM  
Jul-17-19 08:30AM  
Jul-11-19 08:30AM  
Jun-28-19 11:38AM  
Jun-27-19 08:00AM  
Jun-19-19 03:56PM  
May-30-19 08:00AM  
May-13-19 05:21PM  
Apr-30-19 06:10AM  
Apr-25-19 12:00PM  
Apr-22-19 08:45AM  
Mar-28-19 04:30PM  
Mar-27-19 10:15AM  
Mar-26-19 08:30AM  
Mar-18-19 08:30AM  
Mar-14-19 01:01PM  
Feb-27-19 06:05AM  
Feb-07-19 08:30AM  
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.